Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Qiagen and Epigenomics to collaborate on cancer testing system

Qiagen and Epigenomics to collaborate on cancer testing system

1st March 2011

Qiagen is entering into a new collaboration with Epigenomics focusing on the development of a new colorectal cancer blood test, based on Epigenomics technology.

The agreement sees Qiagen gain the rights to develop a testing method based on its partner's proprietary biomarker mSEPT9 and certain DNA methylation analysis innovations, as well as receiving an option to commercialise the product.

This option will last for two years and would see Epigenomics receive additional payments in addition to the upfront fee if it is exercised, while Qiagen would also pay royalties based on the test's sales.

Qiagen intends to make the new assay compatible with its modular molecular testing platform QIAsymphony and will be supported by Epigenomics during the research and development phase.

Ulrich Schriek, vice-president for global business development at Qiagen, said: "Prevention assays are key contributors to early detection of disease and to significant reduction of disease burden."

Last month, the science company published its financial report for 2010, noting an eight percent growth in sales compared to 2009.ADNFCR-8000103-ID-800435777-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.